Form 4: Beam Therapeutics SVP, Finance and Treasurer, Bethany J Cavanagh, Reports Acquisition of 10,000 Shares of Common Stock

Bethany J Cavanagh, SVP, Finance and Treasurer of Beam Therapeutics, reports the acquisition of 10,000 shares of common stock through restricted stock units.

Summary

• On March 31, 2025, Bethany J Cavanagh, SVP, Finance and Treasurer of Beam Therapeutics Inc. (BEAM), acquired 10,000 shares of common stock.
• These shares were obtained through restricted stock units (RSUs) granted under the company's 2019 Equity Incentive Plan.
• The RSUs vest in four equal installments annually, contingent upon continued service with Beam Therapeutics.
• Following this transaction, Cavanagh directly owns 47,527 shares of Beam Therapeutics common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to stock options vesting. While insider ownership is generally positive, this is an expected event.

Positives

• The acquisition of shares by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting of the RSUs is contingent upon the Reporting Person's continued service with BEAM through each vesting date.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders.

Stakeholder Impact

• The transaction increases the executive's stake in the company, aligning their interests with those of shareholders.

Key Dates

Keywords

Beam Therapeutics, Insider Trading, Form 4, Stock Acquisition, Restricted Stock Units, Equity Incentive Plan, Beneficial Ownership, Cavanagh, BEAM